Osteoporosis, Postmenopausal
154
13
20
107
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
27 trials with published results (18%)
Research Maturity
107 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.2%
5 terminated out of 154 trials
95.5%
+9.0% vs benchmark
40%
62 trials in Phase 3/4
25%
27 of 107 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 107 completed trials
Clinical Trials (154)
Combined Anabolic Therapy
The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
Romosozumab Use to Build Skeletal Integrity
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
Mechanisms of Anabolic Osteoporosis Therapy
Telerehabilitation Versus Traditional Balance Training in Women With Osteoporosis.
Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship
Effect of Mechanical Loading With PTH on Cortical Bone
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
Sequential Therapies After Osteoanabolic Treatment
Efficacy of OsteoBor in Postmenopausal Osteoporosis